Objective-To assess the effect of a Mediterranean diet (MedDiet) with and without weight loss (WL) on apolipoprotein B 100 (apoB 100 ) metabolism in men with metabolic syndrome. Approach and Results-The diet of 19 men with metabolic syndrome (age, 24-62 years) was first standardized to a North American isoenergetic control diet for 5 weeks, followed by an isoenergetic MedDiet for an additional 5 weeks under full-feeding conditions (MedDiet−WL). Participants next underwent a 20-week supervised WL program under free-living conditions (−10.2±2.9% body weight; P<0.01) and finally consumed the MedDiet (5 weeks) under weightstabilizing feeding conditions (MedDiet+WL). In vivo kinetic of apoB 100 was assessed in the fasted state at the end of the 3 controlled diets using a bolus of D 3 -leucine. Compared with the control diet, MedDiet−WL reduced low-density lipoprotein (LDL)-apoB 100 pool size (−14.2%, P<0.01) primarily through an increase in LDL-apoB 100 fractional catabolic rate (+30.4%, P=0.02) and increased LDL particle size (P<0.01) but had no effect on very-LDL (VLDL)-apoB 100 pool size or triglyceride concentrations, despite a significant increase in VLDL-apoB 100 fractional catabolic rate (+25.6%; P=0.03). MedDiet+WL had no further effect on LDL-apoB 100 pool size and fractional catabolic rate but further increased LDL particle size and reduced VLDL-apoB 100 pool size versus the control diet primarily through an increase in VLDL-apoB 100 fractional catabolic rate (+30.7%; P<0.01).
I ncreased plasma concentrations of low-density lipoprotein cholesterol (LDL-C) are not considered a typical feature of metabolic syndrome (MetS), but they remain a powerful risk factor for coronary heart disease in this population. 1 MetS is frequently accompanied by elevated plasma triglyceride (TG) and apolipoprotein B 100 (apoB 100 ) concentrations, together with an increase in the proportion of small dense LDL particles. 2 This dyslipidemia is thought to be mainly attributable to an increased production rate of very-LDL (VLDL), combined with reduced catabolic rate of LDL particles. 3 Elevated apolipoprotein CIII (apoCIII) concentrations, 4 as well as increased activities of cholesteryl ester transfer protein (CETP) and hepatic lipase, 5, 6 may also contribute to the typical dyslipidemic state of MetS. Indeed, apoCIII modulates lipoprotein metabolism through its inhibitory effect on lipoprotein lipase and on the hepatic uptakes of VLDL and remnant particles. 7 CETP and hepatic lipase are implicated in the remodeling of LDL and in the formation of small dense LDL particles. 8 The Prevención con Dieta Mediterránea (PREDIMED) study recently showed that adhering to a Mediterranean diet (MedDiet) supplemented with nuts or olive oil significantly decreased the incidence of major cardiovascular events in high-risk subjects, even in the absence of weight loss (WL), compared with a low-fat diet. 9 The extent to which the cardioprotective effects of MedDiet in PREDIMED are attributable to changes in LDL-C concentrations and features of MetS is yet unknown. 9 Both WL and adherence to MedDiet have been shown to improve several features of MetS. 10, 11 It is, therefore, important to consider changes in body weight when assessing the effect of MedDiet on health outcomes because adherence to MedDiet in most randomized controlled studies has been associated with a concurrent reduction in body weight. 12 
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We have recently shown under controlled feeding conditions that consumption of MedDiet in the absence of WL reduces LDL-C concentrations in men with MetS, with no further effect with WL. 13 But little is known about the mechanisms underlying the effect of MedDiet on LDL-C concentrations and other apoB 100 -containing lipoproteins.
The present analysis aimed to investigate the in vivo mechanisms underlying the effect of a traditional MedDiet in the absence and presence of WL on the metabolism of apoB 100containing lipoproteins in men with MetS. Data presented here represent secondary analyses of a previously published clinical study. 13 In vivo apoB 100 kinetic was investigated using a bolus of D 3 -leucine in the fasted state. We hypothesized based on previous analysis of changes in plasma lipid levels 13 that consumption of MedDiet, independent of WL, increases the catabolism of LDL-apoB 100 in men with MetS and that this effect is not amplified by WL.
Materials and Methods
Materials and Methods are available in the online-only Supplement. Figure 1 illustrates the experimental design of this fixed-sequence study. Ten participants of the 29 initially recruited were excluded from analyses. 13 Two subjects dropped out during the first phase of the study (control diet), and we excluded 8 subjects because of a lack of compliance to one of the isoenergetic diets or to the WL prescription (WL >5%), which were eligibility criteria defined a priori. 13 The final sample included 19 men with MetS, for whom kinetic data from all phases are available. Table 1 shows the characteristics of participants at screening. Based on the food checklist, the overall compliance during the 3 controlled isoenergetic dietary phases of the study was 97.9±1.8%. Body weight and waist circumference were reduced by 10.2±2.9% (P<0.001) and 8.6±3.3 cm (P<0.001), respectively, after the MedDiet+WL compared with control diet. Data pertaining to the effect of the nutritional intervention on several cardiovascular risk factors and features of the MetS have been previously published. 13 Metabolic variables and electrophoresis characteristics of LDL particles measured after each dietary phase are presented in Table 2 . As shown previously, consumption of MedDiet−WL significantly reduced LDL-C concentrations by 9.9% compared with the control diet, and there was no further change after MedDiet+WL. 13 MedDiet−WL had no effect on plasma VLDL-TG concentrations and on the VLDL-TG/VLDL-apoB ratio versus the control diet. Consumption of MedDiet−WL significantly reduced VLDL-apoCIII concentrations (−41.5%; P<0.05) and the proportion of LDL <25.5 nm (P<0.05) and significantly increased LDL particle size (P<0.05) compared with the control diet. MedDiet−WL versus the control diet also reduced serum CETP (−7.0%) and hepatic lipase (−7.1%) concentrations and increased endothelial lipase concentrations (+13.7%; all P<0.05). MedDiet+WL significantly reduced plasma VLDL-TG concentrations (−28.5%; P<0.01) compared with the control diet but had no effect on the VLDL-TG/VLDL-apoB ratio. MedDiet+WL was associated with a further increase in LDL particle size and further reduction in VLDL-apoCIII concentrations (both P<0.05) compared with MedDiet−WL. Table 3 and Figure 2 present the VLDL, intermediate-density lipoprotein (IDL), and LDL apoB 100 kinetic data after each dietary phase. MedDiet−WL increased VLDL-apoB 100 fractional catabolic rate (FCR; +25.6%; P=0.03) but had no significant effect on VLDL-apoB 100 production rate (PR; + 15.8%; P=0.46) and VLDL-apoB 100 pool size (PS; −9.1%; P=0.21) compared with the control diet. MedDiet−WL did not appreciably alter IDL-apoB 100 PS, FCR, and PR. MedDiet−WL decreased LDL-apoB 100 PS (−14.2%; P<0.01) and increased LDL-apoB 100 FCR (+30.4%; P=0.02), with no change in LDL-apoB 100 PR (+14.3%; P=0.21) compared with the control diet. Finally, MedDiet−WL tended to increase the absolute conversion rates of VLDL to IDL (+55.1%; P=0.09) and IDL to LDL (+48.3%; P=0.06) compared with the control diet.
Results
MedDiet+WL reduced VLDL-apoB 100 PS (−10.6%; P=0.04), increased VLDL-apoB 100 FCR (+30.7%; P<0.01), and tended to increase VLDL-apoB 100 PR (+27.8%; P=0. 20 absolute conversion rates of VLDL to IDL (+69.2%; P=0.03) and IDL to LDL (+52.4%; P=0.04) compared with the control diet. Finally, MedDiet+WL had no further significant effect on the PS and FCR of LDL-apoB 100 compared with MedDiet−WL.
Discussion
To the best of our knowledge, this is the first study documenting the mechanisms underlying the change in apoB 100 -containing lipoprotein metabolism after consumption of a traditional Mediterranean eating pattern in men with MetS, with particular interest for the potential confounding effect of concurrent WL. Individuals with visceral obesity and MetS are characterized by a high secretion of VLDL-apoB 100 , reduced clearance of apoB 100 -containing particles, and often have a predominance of small dense LDL compared with normal weight controls. 3, 16 Our results suggest that consumption of MedDiet, even in the absence of WL, improves the perturbed metabolism of LDL particles that characterizes MetS. However, short-term consumption of MedDiet does not seem to appreciably alter VLDL concentrations and metabolism, unless accompanied by significant WL.
Specifically, consumption of MedDiet−WL significantly increased VLDL-apoB 100 FCR compared with the control diet but had no significant effect on VLDL-apoB 100 PR. Part of the increase in VLDL-apoB 100 FCR after MedDiet−WL may be attributed to a concurrent reduction in apoCIII concentrations in this fraction. These changes, however, did not translate into significant change in VLDL-apoB 100 PS or TG concentrations. However, MedDiet+WL led to a significant reduction in VLDL-apoB 100 PS and TG concentrations compared with the control diet. These changes seemed to be mainly attributable to an increase in the VLDL-apoB 100 FCR rather than to a change in VLDL-apoB 100 PR, which in fact was increased, albeit nonsignificantly, rather than reduced.
The +15% and +29% increase in VLDL-apoB 100 PR with MedDiet without and with WL, respectively, needs to be addressed, despite failing to achieve statistical significance. An increase in VLDL production with a healthy diet or WL in men with MetS is counterintuitive. Production rate is Values are presented as mean±SE and percentage of change. LDL-C, total apoB 100 , and insulin concentrations have been published previously. 13 VLDL-TG concentrations have been previously published 14, 15 but on a different number of subjects. Apo indicates apolipoprotein; C, cholesterol; CETP, cholesteryl ester transfer protein; HDL, highdensity lipoprotein; LDL, low-density lipoprotein; MedDiet, Mediterranean diet; TG, triglycerides; VLDL, very-low-density lipoprotein; and WL, weight loss.
*Analyses presented here are based on the PROC MIXED procedure in SAS. †Significantly different from the control diet, P<0.05. ‡Significantly different from MedDiet−WL, P<0.05. §Analysis was performed on log-transformed values. ‖HDL-apoCIII was calculated as total plasma apoCIII-VLDL-apoCIII. February 2014 determined as the direct product of FCR and PS. Because VLDL-apoB 100 PS was reduced after MedDiet+WL, one must assume that the VLDL-apoB 100 FCR increase may have had a greater effect on determining the increase in VLDL-apoB 100 PR. Important variability in the PR response to both MedDiet within the context of our sample size of n=19 may have limited our capacity to detect a significant change in this variable. We also stress that the effect of WL on VLDL-apoB 100 PR while on MedDiet was smaller than expected based on previous WL studies. 17 We suspect that consumption of MedDiet may have mitigated the effect of WL per se on VLDL turnover. We also stress that our study was not designed specifically to document the effect of WL per se on apoB 100 kinetics. Our data indicated that the reduction in plasma LDL-C concentrations with MedDiet in the absence of WL 18 is primarily attributable to enhanced LDL clearance rate rather than to change in LDL production rate. Combining WL to MedDiet increased the production rate of LDL-apoB 100 versus the control diet, but we think this is attributable, at least partly, to a parallel enhancement of VLDL particle turnover after MedDiet+WL. MedDiet+WL accelerated the conversion rate of VLDL to IDL and IDL to LDL and, to a lesser extent, of VLDL to LDL. This increase in LDL-apoB 100 PR with MedDiet+WL had no effect on plasma LDL-C or LDL-apoB 100 concentrations, which were not further modified after WL. These data support the concept that change in LDL-apoB 100 FCR is the primary determinant of variations in LDL concentrations with MedDiet, irrespective of WL.
The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to modulate the degradation of the LDL receptor and consequently, LDL particle clearance. 19 Specifically, PCSK9 concentrations have been shown to be inversely correlated with LDL-apoB 100 FCR. 20 We reported previously that consumption of MedDiet, irrespective of WL, significantly reduced plasma PCSK9 concentrations. 18 Thus, part of the increase in LDL-apoB 100 FCR with MedDiet may be attributed to a downregulation of PCSK9. The increase in LDL particle size and the reduction in the proportion of small dense LDL with MedDiet in the absence of WL may have also contributed to the accelerated clearance of LDL. Small dense LDL particles have a lower affinity for the LDL receptor and have been shown to be cleared less rapidly from the circulation than large LDL particles. 21, 22 Individuals with MetS are characterized by TG-enriched large VLDL particles 23 and elevated apoCIII concentrations. 4 VLDL-apoB 100 catabolism is delayed in MetS subjects partly through the inhibitory effect of apoCIII on lipoprotein lipase activity. 4 These aberrations, together with elevated CETP activity in MetS, 6 contribute to the formation of small dense LDL particles. Elevated plasma TG concentrations enhance the heteroexchange of neutral lipids facilitated by CETP, leading to the formation of TG-enriched LDL particles. 24 TG and phospholipids within LDL are hydrolyzed by the actions of both hepatic lipase and endothelial lipase, leading to the generation of small dense LDL particles. 24, 25 In our study, the reduction in VLDL-apoCIII concentrations seen after the MedDiet−WL versus the control diet was significantly and negatively correlated with the increase in LDL size (r= −0.46; P<0.05, data not shown). Therefore, lower concentrations of VLDL-apoCIII, CETP, and hepatic lipase, along with an increase in the FCR of VLDL-apoB 100 , may explain, at least to some extent, the significant increase in LDL particles size after MedDiet in men with MetS even in the absence of WL. 24 This hypothesis is supported by the fact that the increase in LDL particle size after MedDiet−WL occurred in the absence of change in plasma VLDL-TG concentrations and that MedDiet+WL further reduced VLDL-apoCIII concentrations and further increased LDL particle size compared with MedDiet−WL. The lower intakes of saturated fatty acids and trans fatty acids, along with the higher intake of monounsaturated fatty acids, are likely to have contributed to the enhanced LDL-apoB 100 catabolism after consumption of MedDiet. It has been reported that saturated fatty acids decrease and monounsaturated fatty acids increase the activity of LDL receptor in animal studies. 26, 27 Studies in the 1980s have suggested that dietary saturated fatty acids lower LDL FCR compared with polyunsaturated fatty acids in humans. 28, 29 Partly consistent with this, consumption of a high saturated fatty acid diet in place of n6 polyunsaturated fatty acids has been associated with higher plasma PCSK9 concentrations. 30 A previous kinetic study has also shown in hypercholesterolemic women that consumption of trans fatty acids is associated with reduced LDL-apoB 100 FCR. 31 Gill et al 32 have shown that isocaloric replacement of saturated fatty acids with monounsaturated fatty acids significantly reduced small LDL 3 concentrations, which is to some extent concordant with our own data. We stress that our study investigated the effect of MedDiet as a whole, and therefore it is not possible to ascribe the observed metabolic changes to 1 particular nutrient.
Our study has strengths and limitations that need to be pointed out. There was no control group to document changes in apoB 100 metabolism over time independent of the intervention. However, the controlled feeding nature of our protocol and consumption of a standardized control diet before consuming MedDiet, which allowed us to minimize interindividual variations in baseline apoB 100 kinetics, are likely to have attenuated this limitation. The use of tracers to investigate apoB 100 metabolism in response to MedDiet with and without WL, the relatively large number of participants for a kinetic study in a longitudinal design, and the high compliance to the 3 predetermined diets are important strengths of the study. Nevertheless, the sample size and the important variability in some of the kinetic parameters may have limited our ability to observe significant change, despite relatively important variations with MedDiet (eg, IDL-apoB 100 and VLDL-apoB 100 PR). In that context, retaining all subjects for the entire duration of the study would have been ideal. However, we stress that 7 of the 8 noncompliant subjects were excluded based on a priori determined WL cutoff (WL >5%) to be eligible for the last phase of the study. Their mean WL was 0.2±2.0 kg. Although retaining these individuals in the study would have provided more statistical power, their lack of compliance would have yielded unreliable data in the context of the WL perspective of the study. The final sample size (n=19) was only 1 subject short of our a priori sample size calculations for VLDL-apoB 100 PR and LDL-apoB 100 FCR. Finally, as indicated above, the design of the study does not allow us to identify which nutrients as part of the MedDiet paradigm are responsible for the change in LDL metabolism.
In conclusion, short-term consumption of MedDiet, independent of WL, decreases plasma LDL-C and LDL-apoB 100 concentrations primarily by increasing the clearance of LDL particles. Our data also indicated that the beneficial effect of MedDiet on LDL particle size phenotype in men with MetS may be amplified by WL. Finally, short-term consumption of MedDiet seems to have a trivial effect on VLDL concentrations and kinetics unless accompanied by significant WL.
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